Pluri Subsidiary Cellav Clears Path for U.S. Commercial Launch of Regenerative Aesthetic Products
PLUR is trading near its 52-week low of $2.22 (8.6% above the low) on elevated volume (5.2× avg).
Summary
Pluri's subsidiary, Cellav, has completed the U.S. cosmetic product listings for two regenerative aesthetic products, Regenativo+ and Placento+, paving the way for commercial launch in 2026. This is a critical step for the small-cap biotech, which recently disclosed an acute liquidity crisis and going concern doubts. The company is now in active discussions with U.S. distributors and strategic partners to secure initial commercial orders in the rapidly expanding medical aesthetics market. This represents a potential new revenue stream and a transition from product development to commercialization.
At the time of this announcement, PLUR was trading at $2.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26M. The 52-week trading range was $2.22 to $5.96. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.